The ENETS-NANETS joint session discussed the potential feasibility and challenges of creating clinical guidelines and trials to enhance global advancements in neuroendocrine neoplasms. Original abstracts focused on SSTR antagonists labeled with novel isotopes such as Terbium-161, new combination options with chemotherapy in managing aggressive neuroendocrine carcinomas and unlocking the power of Artificial Intelligence to transform NET management.

A special session dedicated to nurses and dietitians highlighted the importance of a multidisciplinary approach to improving patients' lives with NETs.